MARKET WIRESeeking Alpha • 23h ago
Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash ConcernsSeeking Alpha report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
Why CABA Stock dropped -5.30% Today — RQD Quant Desk Flash
$1.43 -5.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.41
Cabaletta Bio Inc. (CABA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $256.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CABA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CABA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Cabaletta Bio Inc. (NASDAQ: CABA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.43 (-5.30% 1D, market cap $256.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CABA ranks #681 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CABA compare to LXEO and LCTX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CABA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $257.6M) and LCTX (Lineage Cell Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $252.9M). Among the 5-stock peer group, CABA leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CABA?
▼
Per CABA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759138), Cabaletta Bio Inc. generated $482.3M in revenue (+37.6% YoY), -$167.9M in net income, and -$132.3M in free cash flow against $165.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.41 (-1.14%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CABA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY CABA SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 38.6 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.69-4.7% Next Q
41
Q2 (-2Q)Grade E$1.61-9.3% Next Q
38
Q3 (-1Q)Grade E$1.46-2.1% Next Q
36
CurrentGrade E$1.43-8.9% Hist 90D α
33
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CABA Turnaround Squeeze
While CABA currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.24) and Max Pain ($1.50) forces dealer call-delta covering toward $4.44.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CABA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CABA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CABA Stock dropped -5.30% Today — RQD Quant Desk Flash
Cabaletta Bio Inc. (CABA) dropped -5.30% to $1.43, trading at 4% of its 52-week range ($1.32 – $4.23). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($1.32 – $4.23) with RSI-14 at 38.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.43 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CABA Headlines & Catalysts
MARKET WIRETradingView • 1d ago
Cabaletta Bio, Inc. Estimates – NASDAQ:CABATradingView report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Cabaletta Bio Slides As Insider Purchases Lose Another US$60kSimply Wall St report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHTimothy Sykes • 1d ago
CABA Stock Slips As Traders Weigh Cash Runway And LossesTimothy Sykes report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMyChesCo • 1d ago
Cabaletta Bio Grants 385,000 Stock Options to New HiresMyChesCo report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStocksToTrade • 1d ago
CABA Stock Slides As Traders Weigh Cash Runway And LossesStocksToTrade report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
BlackRock updates its Cabaletta Bio (CABA) stake report, with sole voting power over 12.8M shares.Stock Titan report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Manila Times • 1d ago
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)The Manila Times report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CABA)
- ✓Walkthrough of CABA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CABA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.66%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.58H $1.58L $1.43C $1.43VOL 3.76M
RES: $3.51SUP: $1.24SMA50: $2.24SMA200: $2.85
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CABA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +37.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on CABA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CABA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CABA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CABA)
Health Care Rank #681 of 1015
⚔️ LXEO vs CABA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CABA vs. LXEO, LCTX, FATE, IPSC)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Cabaletta Bio Inc. (CABA) ranks #681 by composite RQD confidence (33/100, grade E) and #536 by equity capitalization ($256.0M). Within this direct 5-issuer industry benchmark cohort, CABA leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with CABA at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CABA
ACTIVE
Cabaletta Bio Inc. | E | 33/100 | — | — | -35.0% | -5.30% | $256.0M | Benchmark Subject |
| LXEO Lexeo Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -2.55% | $257.6M | /lxeo-vs-caba → |
| LCTX Lineage Cell Therapeutics Inc. | E | 20/100 | — | — | -35.0% | +1.00% | $252.9M | /lctx-vs-caba → |
| FATE Fate Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -3.36% | $249.2M | /fate-vs-caba → |
| IPSC Century Therapeutics Inc. | E | 18/100 | — | — | -14.1% | +0.68% | $266.2M | /ipsc-vs-caba → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001759138 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cabaletta Bio Inc. (CABA) reported GAAP revenue of $482.3M (+37.6% vs. FY2024 revenue of $350.4M , and +130.7% cumulative change since FY2023) , GAAP net income of -$167.9M, operating cash flow of -$131.1M, and free cash flow of -$132.3M (-46.3% YoY). On the balance sheet, CABA closed FY2025 with $165.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $482.3M | -$167.9M | -$131.1M | -$132.3M | $165.1M | — |
| FY2024 (FY) | 2024-12-31 | $350.4M | -$115.9M | -$88.2M | -$90.4M | $185.0M | — |
| FY2023 (FY) | 2023-12-31 | $209.0M | -$67.7M | -$53.5M | -$53.5M | — | — |
3. CABA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CABA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Cabaletta Bio Inc. (NASDAQ: CABA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.43 (-5.30% 1D, market cap $256.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CABA ranks #681 in composite RQD confidence.
How does CABA compare to LXEO and LCTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CABA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $257.6M) and LCTX (Lineage Cell Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $252.9M). Among the 5-stock peer group, CABA leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CABA?
Per CABA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759138), Cabaletta Bio Inc. generated $482.3M in revenue (+37.6% YoY), -$167.9M in net income, and -$132.3M in free cash flow against $165.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CABA trading relative to its 50-day, 200-day, and 52-week technical levels?
CABA last traded at $1.43 (-5.30% on volume of 5,685,606 shares), positioning the stock -36.16% below its 50-day simple moving average ($2.24) and -49.82% below its 200-day simple moving average ($2.85). Across its 52-week range of $1.32 to $4.23, CABA sits at the 3.8% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).
ROARABLE RATING BRIEF • RQD 33/100 (E)
✓ SEC XBRL & RQD VERIFIED
CABA — Cabaletta Bio Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Cabaletta Bio Inc. (CABA) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.43 (-5.30% 1D, market capitalization $256.0M).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Cabaletta Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The market capitalization is $0.3B. Reported revenue for FY 2025 is —, consistent with the absence of revenue in the reported periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cabaletta Bio Inc. (CABA) reported $482.3M in annual revenue (up from $350.4M in FY2024, +37.6% YoY) and -$167.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($209.0M revenue, -$67.7M net income) through FY2025, CABA scaled operating cash flow to -$131.1M and free cash flow to -$132.3M, backed by $165.1M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.32 – $4.23 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Supply chain: NONE; butterfly links: none; proprietary signals: none. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The sector classification (Health Care / Biological Products) and beta of 1.
- Key Question #1: Can CABA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $482.3M and free cash flow of -$132.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is CABA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
CABA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Cabaletta Bio Inc. (CABA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Seeking Alpha • 23h ago
Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns Seeking Alpha report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Cabaletta Bio, Inc. Estimates – NASDAQ:CABA TradingView report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Cabaletta Bio Slides As Insider Purchases Lose Another US$60k Simply Wall St report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Timothy Sykes • 1d ago
CABA Stock Slips As Traders Weigh Cash Runway And Losses Timothy Sykes report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MyChesCo • 1d ago
Cabaletta Bio Grants 385,000 Stock Options to New Hires MyChesCo report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH StocksToTrade • 1d ago
CABA Stock Slides As Traders Weigh Cash Runway And Losses StocksToTrade report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
BlackRock updates its Cabaletta Bio (CABA) stake report, with sole voting power over 12.8M shares. Stock Titan report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Manila Times • 1d ago
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) The Manila Times report covering Cabaletta Bio Inc. (CABA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CABA Bull vs. Bear Conversation Board — What's Your Call at $1.43?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CABA 🐻 33% BEARISH CONVICTION
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH
🎯 Target: $1.80 (+19.2%)
📌 Pinned Debate The stock trades at $1.59, near the low end of its $1.32 to $4.23 52-week range, and the Forensic Balance Sheet pillar (10/20, Altman Z
Don't sleep on CABA's setup in Health Care. The stock trades at $1.59, near the low end of its $1.32 to $4.23 52-week range, and the Forensic Balance Sheet pillar (10/20, Altman Z 2.5) is the strongest of the five RQD pillars.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (33/100) backs up the fundamental quality.
RetailWhale_TX 🐂 BULL
Both sides have a point here — CABA's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH
🎯 Target: $1.28 (-15.2%)
Spot @ $1.51 Reported operating losses widened from -$74.7M in FY 2023 to -$172.2M in FY 2025 with zero revenue, ROIC at -35%, and FCF yield at 0%,
Here is the bear case nobody on the bull side wants to address on CABA: Reported operating losses widened from -$74.7M in FY 2023 to -$172.2M in FY 2025 with zero revenue, ROIC at -35%, and FCF yield at 0%, while cash fell from $164.0M to $83.0M.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.